Compositions and methods for treating cns disorders
US-2017233433-A1 · Aug 17, 2017 · US
Compositions and methods for treating CNS disorders
US10870677B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10870677-B2 |
| Application number | US-201916365123-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 26, 2019 |
| Priority date | Oct 16, 2014 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable said thereof; wherein, R 1 , R 2a , R 2b , R 3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
First claim
Opening claim text (preview).
What is claimed is: 1. A process for preparing a compound of Formula (A14): the process comprising, treating a compound of Formula (A13): with trimethyl(trifluoromethyl)silane and tetra-n-butylammonium fluoride, wherein the process is performed in tetrahydrofuran at room temperature.
Assignees
Inventors
Classifications
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title
- C07J43/003Primary
not condensed · CPC title
with double bond in position 17 (20) · CPC title
- A61K31/58Primary
containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) · CPC title
Benzotriazoles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10870677B2 cover?
- Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable said thereof; wherein, R 1 , R 2a , R 2b , R 3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatm…
- Who is the assignee on this patent?
- Sage Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J43/003. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).